Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments [Globe and Mail, The (Toronto, Canada)]
Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target raised by analysts at Piper Sandler from $7.00 to $10.00. They now have an "overweight" rating on the stock.
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription [Yahoo! Finance]
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More [Yahoo! Finance]
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study [Yahoo! Finance]